Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.395 USD | +2.34% |
|
+21.43% | +36.90% |
01/07 | Raymond James Initiates AxoGen at Outperform With $13 Price Target | MT |
24/06 | Axogen, Inc. Announces Full Launch of Avive+ Soft Tissue Matrix | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.90% | 40Cr | |
+4.77% | 21TCr | |
+8.74% | 19TCr | |
+27.70% | 16TCr | |
+34.03% | 11TCr | |
+2.17% | 6.55TCr | |
+13.75% | 5.29TCr | |
-3.30% | 4.53TCr | |
-3.73% | 3.97TCr | |
+6.39% | 3.77TCr |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- AxoGen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2020